Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

After a string of mid-stage failures this year, plus a blow to its major depression commercial plans last year, Sage ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

CDMO OmniaBio on Thursday opened a commercial-stage cell manufacturing facility that has AI capabilities worth around CAD ...

Plus, news about Kezar Life Sciences and Concentra Biosciences: Viatris, Lexicon Pharmaceuticals sign licensing deal for cardio drug: Per the agreement, Viatris will pay $25 million ...

Bavarian Nordic’s mpox vaccine Jynneos generated a similar immune response in adolescents as it did in adults, offering ...

A month after making a foray into the bustling radioligand field, Sanofi is further allying itself with Orano Med, paying ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

An experimental therapy designed to change a single letter of short-lived mRNA molecules has corrected a genetic mutation ...

Takeda will not move forward with Wave Life Sciences on a Huntington’s disease drug, ending their collaboration that first ...

Novavax’s post-Covid path ran into a speed bump Wednesday, as the company announced a clinical hold on its Covid-influenza ...

Investors have been placing bets into startups that help members of low-income households on Medicaid insurance get care. A ...